A Study of Pasritamig (JNJ-78278343) in Combination With JNJ-86974680 for Treatment of Prostate Cancer

The purpose of this study is to identify the recommended phase 2 combination dose (RP2CD) of Pasritamig in combination with JNJ-86974680 in Part 1 (Dose finding) of the study and to determine how safe and tolerable the RP2CD is for treatment of participants with advanced prostate cancer in Part 2 (Dose expansion) of study.

Trial Details

NCT ID
NCT07319871
Phase
PHASE1
Sponsor
Janssen Research & Development, LLC
Status
RECRUITING
Cancer Type
Prostate Cancer
Interventions
  • Pasritamig
  • JNJ-86974680
Locations (sample)
  • Sarasota, Florida, United States|27.33643,-82.53065
  • New York, New York, United States|40.71427,-74.00597
  • Cleveland, Ohio, United States|41.4995,-81.69541
  • Manchester, United Kingdom|53.48095,-2.23743
  • Sutton, United Kingdom|51.35,-0.2

Key Eligibility Criteria

  • Histologically confirmed adenocarcinoma of the prostate. Primary small cell carcinoma, carcinoid tumor, neuroendocrine (NE) carcinoma, or large cel…
  • Metastatic castration-resistant prostate cancer (mCRPC) that is metastatic either to bone, any lymph node, or both without clear evidence of metast…
  • Prior orchiectomy or medical castration (for example, must be receiving ongoing androgen deprivation therapy with a gonadotropin-releasing hormone …
  • Prostate-specific antigen (PSA) greater than or equal to (\>=) 2 nanograms per milliliters (ng/mL) at screening

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Prostate Cancer Trials on Trialify →